

MS.4/ 27.02.2019

Acute Leukemia: AML

Abdallah Al-Abbadi.MD.FRCP.FRCPath

Feras Fararjeh MD

Case 9: Acute Leukemia

29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk and limbs.

Physical findings

Spleen ++. Gum &

Skin shown.

Fever 40

BP 100/70 P 102


Hb 9, WBC 54K

Blasts 80%, Plt 24K


PT 18/13, PTT 40/32,

Urine: RBC +3, WBC +++, Bacteria

+++. Bld culture + E.Coli.




Why is AML a disease of getting old?




Source: SEER data 2005-2009.

AML: Epidemiology Incidence of AML Increases with Age




AML: Epidemiology Survival Decreases with Age



Available at <http://seer.cancer.gov/statfacts/html/amyl.html> and <http://seer.cancer.gov/statfacts/html/alyl.html>. Accessed September 5, 2007.

Incidence of clonal hematopoiesis increases with age



Summary

Why do we develop AML as we get older?

Hematopoietic stem cells acquire mutations over their lifetime.

Most are benign (passenger).

Occasionally one leads to clonal hematopoiesis.

Each division within this clone results in further mutations, and facilitate subclonal evolution and progression to MPD/MDS/AML.

AML: Definition

- **De novo AML**
- **Secondary AML**
 - Clinical history of:
 - Myelodysplastic syndrome
 - Myeloproliferative disorder
 - Prior exposure to radiation, select chemicals, or chemotherapy

AML: Classification French-American British (FAB)

M0	Undifferentiated
M1	Myeloblastic without maturation
M2	Myeloblastic with maturation
M3	Promyelocytic
M4	Myelomonocytic
M5	Monocytic
M6	Erythroid
M7	Megakaryoblastic*

*Added in 1985

Bennett JM et al. *Br J Haematol*. 1976;33:451-458.; Bennett JM et al. *Ann Intern Med*. 1985;103:460-46

AML: Classification World Health Organization (WHO)

- **AML with recurrent genetic abnormalities**
 - t(8;21)(q22;q22)
 - inv(16)(p13q22) or t(16;16)(p13;q22)
 - t(15;17)(q22;q12)
 - 11q23 abnormalities
- **AML with multilineage dysplasia**
- **AML and myelodysplastic syndromes (MDS); therapy related**
- **AML not otherwise categorized**

AML: Prognostic Factors

- Age
- Cytogenetics
- Molecular mutation
- Secondary AML
- Performance status
- Leukocyte count at presentation

AML: Prognostic Factors


Frequency of Cytogenetic Risk Groups

	Karyotype	Frequency (%)
Favorable	t(8;21)	5 - 10
	inv16	5 - 10
	t(15;17)	5 - 10
Intermediate	Diploid,-Y	40 - 50
Unfavorable	-5 / -7	20 - 30
	+8	10
	11q23, 20q-, other	10 - 20

AML: Karyotype and Prognosis

Results from Cancer and Leukemia Group B (CALGB 8641)

Overall Survival Patients age 15 - 86 with untreated AML



Jabbour EJ et al. *Mayo Clin Proc.* 2006;81(2):247-260.

Byrd JC et al. *Blood.* 2002;100:4325-4336.

AML: Treatment Overview

Remission Induction

- **Goal to reduce tumor burden & restore normal hematopoiesis**
- **“7 + 3”: Continuous infusion cytarabine x 7 days and an anthracycline x 3 days remains standard of care**
 - ? Best anthracycline
 - ? Intensification with high dose cytarabine (HDAC) or etoposide
 - ? Timed sequential chemotherapy

AML: Treatment Overview

Post-Remission (Consolidation) Therapy

- Once in CR, long-term survival requires post-remission treatment
 - Chemotherapy **versus**
 - Allogeneic stem cell transplant **versus**
 - Autologous stem cell transplant

New approach in treating AML

1- Risk stratification


2- Incorporation of Monoclonal antibodies

3- Incorporation of small molecules and targeted therapy



Promyelocytic leukemia M3

1. Associated with t (15;17) involving the retinoic acid receptor (RAR) gene .
 2. Good prognosis category.
 3. Commonly associated with **DIC**.
- Prominent Auer rods.

Auer rods in AML



t(15;17) translocation in AML



M4: Myelomonocytic leukemia

- With inverted 16 and associated eosinophilia
this is a good prognostic category
- Associated with leukemia cutis.
- CNS disease may occur.

Treatment aml/m3

- **Tretinoin (all tran retinoic acid)** is an oral drug that induces the differentiation of leukemic cells bearing the t(15;17); it is not effective in other forms of AML.
- APL is responsive to **cytarabine** and **daunorubicin**, but about 10% of patients treated with these drugs die from DIC induced by the release of granule components by dying tumor cells.

ATRA Syndrome

- Tretinoin does not produce DIC but produces another complication called the *retinoic acid syndrome*.
- Occurring within the first 3 weeks of treatment, it is characterized by **fever, dyspnea, chest pain, pulmonary infiltrates, pleural and pericardial effusions, and hypoxia**.
- The syndrome is related to adhesion of differentiated neoplastic cells to the pulmonary vasculature endothelium.
- Glucocorticoids, chemotherapy, and/or supportive measures can be effective.
- The mortality of this syndrome is about **10%**.

Case 9 B

A 19 yr old male has been complaining of fatigue, joint pain for 2 wks. He was admitted because he had a high fever. P/E he looked ill and pale, with Temp 40, BP 100/70, p 104, he had generalized LN enlargement, badly infected tonsil. His spleen was enlarged. Hb 9.5g/dl, plts 45k, WBC 90k: blasts 88%, other cells 12%. LDH 1600, Uric acid 13, Ca 7, PO4 5, Creat 3, K, 6.1, PT, PTT, TT, Nml.



Flow

CD19(+), Tdt(+),

CD10(+), Cylg(-),

Karyotyping normal

PAS +++



Common manifestations of acute leukemia

1-Manifestations of BM replacement

Anemia

Thrombocytopenia

Neutropenia

2-Infiltration of extra BM tissues:

LN, Gums, skin, CNS, others

3-Release of granules/ metabolites:

DIC/ gout, ARF

4-Hyperviscosity

Biology of Adult Acute Lymphoblastic Leukemia

Classification:

- Morphologic Features
- Immunophenotyping

Morphologic subtypes of acute lymphoblastic leukemias (FAB classification)

<u>Subtype</u>	<u>Morphology</u>	<u>Occurrence (%)</u>
L1	Small round blasts clumped chromatin	75
L2	Pleomorphic larger blasts clefated nuclei, fine chromatin	20
L3	Large blasts, nucleoli, vacuolated cytoplasm	5


Antigen independent phase

Bone marrow

Blood

Antigen dependent phase

Secondary lymphoid organs



Immunologic classification of acute lymphoblastic leukemias

B-lineage (80%)

Markers

Pro-B	CD19(+), Tdt(+), CD10(-), Cylg(-),
Common	CD19(+), Tdt(+), CD10(+), Cylg(-),
Pre-B	CD19(+), Tdt(+), CD10(+), Cylg(+), Smlg(-)
Mature-B	CD19(+), Tdt(+), CD10(±), Cylg(±), Smlg(+)

T-lineage (20%)

Pre-T	CD7(+), CD2(-), Tdt(+),
Mature-T	CD7(+), CD2(+), Tdt(+),

Chromosomal/molecular abnormalities with prognostic significance in ALL

Better prognosis

- normal karyotype
- hyperdiploidy

Poor prognosis

- t (8; 14)
- t (4; 11)

Very poor prognosis

- t (9; 22); BCR/ABL (+)

Risk classification in ALL

- 1. Standard risk**
- 2. High risk**
- 3. Very high risk**

High-risk ALL/ very high risk

1. Pre - T
2. Pro - B
3. Age > 35 years,
4. WBC > 30 G/L in B-ALL
> 100 G/L in T-ALL
5. No remission after 4 weeks of induction therapy
6. Chromosome Philadelphia - positive or BCR/ABL (+)

In ALL the choice of treatment-strategy depends on:

1. Risk Stratification
2. Immunophenotype of leukemic cells
 - T lineage,
 - early B lineage,
 - mature B lineage,
3. Age and biological condition
4. Goal of treatment

Prognostic Features

Characteristic
Age < 1 or > 9 years
WBC > 50,000/mm ³
Adverse cytogenetics
t(9;22)
t(4;11) or other 11q23 abn
Hypodiploidy (< 45 chromosomes)
Minimal Residual Disease

Treatment Approach in ALL

CNS Prophylaxis

Intrathecal methotrexate, Ara-C, Steroids, Craniospinal irradiation

INDUCTION

1 month

Anthracycline
Vincristine
Cyclophosphamide
L-asparaginase
Methotrexate
Ara-C
Steroids

GOAL: rapidly restore normal

CONSOLIDATION / INTENSIFICATION

4-8 months

Chemotherapy
Allogeneic Stem Cell Transplant

GOAL: prevent emergence of resistant clones
eliminate residual disease

MAINTENANCE

2-3 years

6-MP
Methotrexate
Vincristine
Steroids

GOAL: eliminate residual disease

Allogeneic BMT for ALL

High risk ALL

Unacceptable minimal residual disease

Availability of a donor

Good performance status

Aim to cure

New approach in treating ALL

- 1- Risk stratification
- 2- Incorporation of Monoclonal antibodies
- 3- Incorporation of small molecules and targeted therapy
- 4- Shorter treatment time
- 5- ? Better outcome and long term survival